Company Analysis Passage Bio, Inc.
1. Summary
Advantages
- Price (10.76 $) is less than fair price (13.25 $)
- The stock's return over the last year (31.48%) is higher than the sector average (-2.93%).
Disadvantages
- Dividends (0%) are below the sector average (0.5317%).
- Current debt level 24.88% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-75.07%) is lower than the sector average (ROE=106.63%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Passage Bio, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 12.1% | -14.5% | 0.1% |
| 90 days | 31.2% | -5.6% | 4.6% |
| 1 year | 31.5% | -2.9% | 20.5% |
PASG vs Sector: Passage Bio, Inc. has outperformed the "Healthcare" sector by 34.41% over the past year.
PASG vs Market: Passage Bio, Inc. has outperformed the market by 10.94% over the past year.
Stable price: PASG is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: PASG with weekly volatility of 0.6054% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (10.76 $) is lower than the fair price (13.25 $).
Price significantly below the fair price: The current price (10.76 $) is 23.1% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-5.95) is lower than that of the sector as a whole (33.49).
P/E vs Market: The company's P/E (-5.95) is higher than that of the market as a whole (-68.72).
5.3. P/BV
P/BV vs Sector: The company's P/BV (11.18) is lower than that of the sector as a whole (260.15).
P/BV vs Market: The company's P/BV (11.18) is lower than that of the market as a whole (51.39).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (129.83).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (148.63).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-10.91) is higher than that of the sector as a whole (-28.84).
EV/Ebitda vs Market: The company's EV/Ebitda (-10.91) is higher than that of the market as a whole (-95.22).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -13% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-13%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-598.11%).
6.4. ROE
ROE vs Sector: The company's ROE (-75.07%) is lower than that of the sector as a whole (106.63%).
ROE vs Market: The company's ROE (-75.07%) is lower than that of the market as a whole (-6.23%).
6.6. ROA
ROA vs Sector: The company's ROA (-51.21%) is lower than that of the sector as a whole (-2.32%).
ROA vs Market: The company's ROA (-51.21%) is lower than that of the market as a whole (38.59%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (-48.75%) is lower than that of the sector as a whole (0.8343%).
ROIC vs Market: The company's ROIC (-48.75%) is lower than that of the market as a whole (9.66%).
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5317%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 15.09.2025 | Lynx1 Capital Management LP 10% Owner |
Purchase | 6.99 | 83 181 | 11 900 |
| 12.09.2025 | Lynx1 Capital Management LP 10% Owner |
Purchase | 6.99 | 138 283 | 19 783 |
| 11.09.2025 | Lynx1 Capital Management LP 10% Owner |
Purchase | 6.96 | 2 262 | 325 |
| 15.07.2025 | OrbiMed Private Investments VI Stockholder |
Purchase | 6.79 | 361 859 | 53 293 |
| 26.06.2025 | ORBIMED ADVISORS LLC 10% Owner |
Sale | 0.33 | 70 375 | 213 257 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
Based on sources: porti.ru
